Latest News

• share
• favorite_border

The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced a multi-year strategic collaboration designed to expedite the research and development of novel engineered tumor infiltrating lymphocytes (TILs) for the treatment of solid tumors. The agreement pairs Obsidian and its novel cytoDRiVE™ technology platform with MD Anderson’s extensive experience and state-of-the-art capabilities in TIL cell therapy, led by the Biologics Development platform, within the Therapeutics Discovery division.

• share
• favorite_border

Sherry Adkins is the recipient of the 2020 Brown Foundation Award for Excellence in Oncology Nursing, MD Anderson's highest nursing honor.

• share
• favorite_border

Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) .

• share
• favorite_border

Through large-scale profiling of protein changes in response to drug treatments in cancer cell lines, researchers at The University of Texas MD Anderson Cancer Center have generated a valuable resource to aid in predicting drug sensitivity, to understand therapeutic resistance mechanisms and to identify optimal combination treatment strategies.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center will host the fifth annual Boot Walk to End Cancer® virtually on Saturday, Nov. 7. The virtual walk will take place online and in neighborhoods across the country in an effort to keep participants, their families and their communities safe and as part of MD Anderson's commitment to prioritizing the health and safety of patients, workforce members and the greater Houston community.

• share
• favorite_border

The Focus Fund GP, LLC, in partnership with The University of Texas MD Anderson Cancer Center, has launched Cancer Focus Fund, LP, an oncology-focused investment fund designed to support the advancement of compelling investigational cancer therapies from late preclinical development through Phase I and Phase Ib/II clinical trials.

• share
• favorite_border

MD Anderson and Allogene today announced a strategic five-year collaboration for preclinical and clinical investigation of allogeneic CAR T cell therapies.

• share
• favorite_border

Phase I trial finds neoadjuvant combination checkpoint inhibitors (anti-CTLA-4 plus anti-PD-1) was well tolerated and showed early signs of activity in certain patients with bladder cancer. These patients cannot be treated with chemotherapy and have no standard treatment options available.

• share
• favorite_border

A study finds that cancer mutations occur in distinct patterns based on the 3D structure of the genome and the underlying cause of the mutation. This helps us to understand cancer better and may lead to new treatment approaches.

• share
• favorite_border

Researchers at The University of Texas MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19 CAR T cell infusion products associated with how patients with large B-cell lymphoma (LBCL) respond to treatment and develop side effects.

• share
• favorite_border

A new data analysis tool developed by researchers at The University of Texas MD Anderson Cancer Center incorporates a user-friendly, natural-language interface to allow biomedical researchers without specialized expertise in bioinformatics or programming languages to conduct intuitive analysis of large datasets.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration to accelerate the development of treatments for significant unmet medical needs in oncology, including patients with brain metastases and those with cancers refractory to available therapies.

• share
• favorite_border

For patients with advanced solid cancers and KRAS G12C mutations, the targeted therapy sotorasib, a KRAS G12C inhibitor, resulted in manageable toxicities and durable clinical benefits, particularly in lung and colorectal cancer, in Phase I study

• share
• favorite_border

New preclinical research from MD Anderson and Navire finds a novel drug targeting SHP2 can overcome multiple paths of therapeutic resistance in lung cancer. Navire will launch a clinical trial of SHP2 inhibitors by the end of 2020.

• share
• favorite_border

Results from a Phase II trial led by researchers at MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with advanced prostate cancer.

• share
• favorite_border

MD Anderson News Release September 08, 2020 The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a  strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex’s pipeline of products for patients with certain types of leukemia, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).

• share
• favorite_border

The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic collaboration to study investigational treatments for patients with a variety of cancer types.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center Board of Visitors (BOV) has named 15 new members and bestowed its highest honor of Life Member on senior members Regina Rogers of Beaumont and Melvyn N. Klein of Corpus Christi.

• share
• favorite_border

For patients with non-small cell lung cancers marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of patients in a Phase I/II trial.

• share
• favorite_border

In a Phase II trial led by MD Anderson researchers, a combination targeted therapy acheived a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.

• share
• favorite_border

Two different types of detectable antibody responses in SARS-CoV-2 (COVID-19) tell very different stories and may indicate ways to enhance public health efforts against the disease, according to researchers at The University of Texas MD Anderson Cancer Center. Antibodies to the SARS-CoV-2 spike protein receptor binding domain (S-RBD) are speculated to neutralize virus infection, while the SARS-CoV-2 nucleocapsid protein (N-protein) antibody may often only indicate exposure to the virus, not protections against reinfection.

• share
• favorite_border

A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center is committed to safely providing patient care and cancer screenings throughout the novel coronavirus (COVID-19) pandemic.

• share
• favorite_border

According to researchers from The University of Texas MD Anderson Cancer Center, the implementation of social distancing policies corresponded with significant reductions in transmission of the SARS-CoV-2 virus and reduced community mobility, both in the U.S. and globally, providing evidence that social distancing is a useful tool in preventing further spread of COVID-19.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center and Sanofi today announced a five-year strategic collaboration to accelerate the development of investigational treatments, including targeted and immune therapies, for patients with cancer.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center and two institutions at The University of Texas at Austin – the Oden Institute for Computational Engineering and Sciences and the Texas Advanced Computing Center (TACC) – today announced a new initiative to build a strong collaboration in Oncological Data and Computational Science.

• share
• favorite_border

In the first study to look at objective measures of sedentary behavior and cancer mortality, researchers from The University of Texas MD Anderson Cancer Center found that greater inactivity was independently associated with a higher risk of dying from cancer.

• share
• favorite_border

A combination of two biomarkers was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors in patients with advanced bladder cancers.

• share
• favorite_border

MD Anderson and Philips today announced a collaboration to aid oncologists around the world to personalize therapy based on their patients' genomic profiles, with the aim of improving patient care.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center and Rakuten Medical, Inc. today announced a strategic alliance collaboration agreement to advance the development of new cancer therapies based on Rakuten Medical’s proprietary IlluminoxTM technology platform.

• share
• favorite_border

Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9556 – Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center. The results of this trial may support a novel course of action for patients with AML harboring an IDH1 mutation who have historically had few treatment options.

• share
• favorite_border

In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)–associated renal cell carcinoma (RCC).

• share
• favorite_border

MD Anderson and Innovent Biologics have announced a strategic collaboration agreement to co-develop Innovent's anti-PD-1 monoclonal antibody for treating rare cancers in the U.S.

• share
• favorite_border

MD Anderson and Ipsen have advanced a new targeted therapy into clinical trials for certain patients with lung and ovarian cancers. Details are being presented at the AACR Annual Meeting.

• share
• favorite_border

New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. Most patients included in the study went on to receive subsequent systemic therapies, which may have affected the survival outcome analysis. The research confirmed previous results showing talazoparib improved patient reported quality-of-life measures over available chemotherapies and had a tolerable safety profile.

• share
• favorite_border

Majority of patients responded in CAR T-cell trial for mantle cell lymphoma. Study showed 93% of patients responded with 67% achieving complete response.

• share
• favorite_border

A subset of patients with metastatic prostate cancer and specific markers of immune activity responded well to treatment with immune checkpoint inhibitors, according to results of a Phase II trial.

• share
• favorite_border

New therapeutic strategies proposed for some lung and kidney cancers. Study shows cancers with high levels of the SLC7A11 gene may respond to glucose transporter inhibitor treatment.

• share
• favorite_border

MD Anderson researchers find that treating T cells with panobinostat and IL-21 re-programs them to a powerful central memory T cell type that persists longer.

• share
• favorite_border

A study led by The University of Texas MD Anderson Cancer Center has found that myelin is surprisingly dynamic, a discovery that has implications for treatment of multiple sclerosis and a type of myelin damage caused by some chemotherapy drugs, often referred to as “chemobrain.”

• share
• favorite_border

Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers. Open-label Phase II study at MD Anderson reports on four cancer types.

• share
• favorite_border

Combined therapy may improve clinical responses for endometrial, colorectal and gastric tumors. Enzyme inhibitor with anti-PD1 checkpoint blockade boosted efficacy over either treatment alone

• share
• favorite_border

Comprehensive profiling of tumor samples taken from patients with osteosarcoma shows that multiple factors contribute to the traditionally poor responses observed from treatment with immune checkpoint inhibitors, according to new research from The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

MD Anderson announces a strategic research collaboration with Denali Therapeutics to develop new targeted therapies for Alzheimer's and other neurodegenerative diseases.

• share
• favorite_border

MD Anderson receives more than $20 million in CPRIT funding for research, clinical translation, prevention and recruitment.

• share
• favorite_border

A study at The University of Texas MD Anderson Cancer Center found that chemotherapy results in increased heterogeneity within small cell lung cancer, leading to the evolution of multiple resistance mechanisms.

• share
• favorite_border

Loss of an important tumor-suppressing gene allows head and neck cancer to spin off signals to nearby nerves, changing their function and recruiting them to the tumor, where they fuel growth and cancer progress.